PRWeek | 2021 Will Be Known As Year Medcomms M&A Went Into Overdrive
Several large agency groups have taken on fresh private equity capital for the first time this year and many others have changed private equity ownership.
In each case, the thesis is simple: buy your way to growth and a full-service proposition.
Full-service medcomms spans everything from pre-clinical R&D strategy through medical affairs and market access work during clinical trials, and across to the marketing and creative work for brand launches (and relaunches) – and everything in between.
Within each bucket there are several niches in a sector known for being highly fragmented.
As the larger medcomms platforms scale and their valuations rise, this has corresponded to smaller agencies also experiencing a rise in valuations.
Deal structures now tend to be more attractive to sellers than in previous years, typically tying agency owners to the growth of the overall acquiring group and not solely the performance of the target company.
The days of the five-year earnout have largely disappeared and been replaced with more favourable win-win arrangements.
As bigger groups have greater firepower to acquire, sellers continue to sell.
The 10 most active medcomms acquirers have bought 19 companies so far in 2021, with many others being acquired by other medcomms agencies or non-healthcare buyers.
The trend from 2021 is that private equity-backed acquirers are accelerating the pace of M&A across Europe and the US, in particular.
Why are we experiencing heightened activity?
The pharma medcomms market is one of the most attractive sectors to operate in. It’s worth more than $10bn in 2021 and is growing 12 per cent annually, with medical affairs and publication work making up the largest budgets across the sub-sectors.
The focus on this sector compared with other industries remains high and I can’t see the spotlight moving off outsourced pharma services for years to come.
The tailwinds keeping the conveyor belt of M&A moving include:
- Fresh private equity capital in the sector.
- A continued focus on pharma and healthcare.
- Outsourcing trends within pharma increasing and staying elevated.
- The need for more complex data and analytical requirements which can only be performed by outsourced specialists.
This all drives the market forward and acts as an additional incentive for new agencies to have innovative services at the core of their business.
One major challenge for top acquirers will be retaining culture and spark, which is often a key reason agencies are so attractive to them. I’ve seen huge strides being made by acquirers to ensure culture remains in place post-acquisition.
Independent agency owners across the pharma and life science space will have a red-hot phone line as the private equity-backed platforms continue to grow through acquisition.
Managing Director James West provides his perspective in PRWeek on private equity trends in the medcomms sector.
- Sign up to receive Lincoln's perspectives
Meet Professionals with Complementary Expertise
I enjoy working closely with clients to overcome challenging situations and to develop strategies to meet their business goals.
Managing Director | Management Board MemberFrankfurt
RealDeals | Yield of Dreams
Originally posted by RealDeals on August 29, 2023. Private debt is growing quickly despite rising interest rates. Recent Preqin data indicated that $33.7 billion was raised in Europe in Q2… Read More
HealthInvestor | CMA Launches Review of Vet Sector
Originally posted by HealthInvestor on September 7, 2023. The Competition and Markets Authority (CMA) has begun reviewing UK veterinary services to uncover how well the market is working for pet… Read More
Conceiving Success: Growth and Consolidation in IVF in APAC and the Middle East
In-vitro fertilization in Asia-Pacific and the Middle East is growing quickly due to several factors; the industry’s rapid growth offers an opportunity for investors to capitalize on momentum. In a… Read More
No Surprises Act Changes U.S. Healthcare System
The implementation of the No Surprises Act (NSA)’s out-of-network (OON) billing restrictions, coupled with its disclosure and transparency requirements, has resulted in significant changes to healthcare financing and consumption across… Read More
Recent Transactions in Healthcare
Lincoln International advised Havencrest Capital Management on its majority investment in Tekton Research
Lincoln International advised Your Way Medicare on its sale to Accretive, a portfolio company of GTCR
Lincoln International advised Seventure and minority shareholders on the sale of TargEDys to Biocodex
Lincoln International advised KPS Capital Partners on its sale of LRE Medical to Gyrus Capital
Lincoln International advised IVC Evidensia, a portfolio company of EQT Partners, on its sale of a group of veterinary practices to Perwyn
Lincoln International advised The Anderson Group on its sale of Parkview Health Services to Flexpoint Ford
Lincoln International advised Hallmarq Veterinary Imaging, a portfolio company of August Equity, on its refinancing
Lincoln International advised Medisolv on receiving a strategic investment from BVP Forge